Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bph.13695 http://scihub22266oqcxt.onion/10.1111/bph.13695 C5406292!5406292!28009437     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Pharmacol 2017 ; 174 (10): 921-32 Nephropedia Template TP {{tp|p=28009437|t=2017. Serelaxin in clinical development: past, present and future |pdf=|usr=}}{{28009437}} gab.com Text Serelaxin in clinical development: past, present and future JO: Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28009437 #FOAvip The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long?term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc Twit Text FOAVip Serelaxin in clinical development: past, present and future ????Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28009437 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28009437 #FOAvip English Wikipedia <ref>{{Cite pmid|28009437}}</ref> Serelaxin in clinical development: past, present and future #MMPMID28009437 Unemori E Br J Pharmacol 2017[May]; 174 (10): 921-32 PMID28009437show ga The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long?term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc äSerelaxin in clinical development: past, present and future (epmc).pdf DeepDyve Pubget Overpricing